ARCHIVES

FDA Approves Xeloda For Colon Cancer; Phase III Data Not Reviewed By ODAC.

This article is from The Cancer Letter archive.

Vol. 27 No. 18 | May 4, 2001

Download PDF Visit The Full Archive

Related Articles

NCI, Advisers Lean To Smaller Increases For R01a, Philosophy Of Spreading Money Among More Grants

January 15, 1982

Gavel Changes Hands At NCAB, Korn advises New Members On Role

February 8, 1991

NIES Issue RFA For Studies On Alternative Types Of Cancer Bioassay

October 31, 1980

NCAB Oks LANs To Links NCI Staff With Each Other, The World

February 14, 1992

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

Presidents’ FY93 Budget Holds NCI To $2 Billion, Gives NIH 5% Increase; Coalition ‘Disapionted’

February 7, 1992